Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis
Top Cited Papers
Open Access
- 6 May 2021
- journal article
- review article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (5), e0251170
- https://doi.org/10.1371/journal.pone.0251170
Abstract
The recovery of other pathogens in patients with SARS-CoV-2 infection has been reported, either at the time of a SARS-CoV-2 infection diagnosis (co-infection) or subsequently (superinfection). However, data on the prevalence, microbiology, and outcomes of co-infection and superinfection are limited. The purpose of this study was to examine the occurrence of co-infections and superinfections and their outcomes among patients with SARS-CoV-2 infection. We searched literature databases for studies published from October 1, 2019, through February 8, 2021. We included studies that reported clinical features and outcomes of co-infection or superinfection of SARS-CoV-2 and other pathogens in hospitalized and non-hospitalized patients. We followed PRISMA guidelines, and we registered the protocol with PROSPERO as: CRD42020189763. Of 6639 articles screened, 118 were included in the random effects meta-analysis. The pooled prevalence of co-infection was 19% (95% confidence interval [CI]: 14%-25%, I2 = 98%) and that of superinfection was 24% (95% CI: 19%-30%). Pooled prevalence of pathogen type stratified by co- or superinfection were: viral co-infections, 10% (95% CI: 6%-14%); viral superinfections, 4% (95% CI: 0%-10%); bacterial co-infections, 8% (95% CI: 5%-11%); bacterial superinfections, 20% (95% CI: 13%-28%); fungal co-infections, 4% (95% CI: 2%-7%); and fungal superinfections, 8% (95% CI: 4%-13%). Patients with a co-infection or superinfection had higher odds of dying than those who only had SARS-CoV-2 infection (odds ratio = 3.31, 95% CI: 1.82–5.99). Compared to those with co-infections, patients with superinfections had a higher prevalence of mechanical ventilation (45% [95% CI: 33%-58%] vs. 10% [95% CI: 5%-16%]), but patients with co-infections had a greater average length of hospital stay than those with superinfections (mean = 29.0 days, standard deviation [SD] = 6.7 vs. mean = 16 days, SD = 6.2, respectively). Our study showed that as many as 19% of patients with COVID-19 have co-infections and 24% have superinfections. The presence of either co-infection or superinfection was associated with poor outcomes, including increased mortality. Our findings support the need for diagnostic testing to identify and treat co-occurring respiratory infections among patients with SARS-CoV-2 infection.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (1DP2AI144244-01)
This publication has 144 references indexed in Scilit:
- The frequency of influenza and bacterial coinfection: a systematic review and meta‐analysisInfluenza and Other Respiratory Viruses, 2016
- Metaprop: a Stata command to perform meta-analysis of binomial dataArchives of Public Health, 2014
- In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication biasJournal of Clinical Epidemiology, 2014
- The CARE GuidelinesDeutsches Ärzteblatt international, 2013
- The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline DevelopmentGlobal Advances in Health and Medicine, 2013
- Bacterial and viral infections associated with influenzaInfluenza and Other Respiratory Viruses, 2013
- Bacterial Coinfection in InfluenzaJAMA, 2013
- Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza PreparednessThe Journal of Infectious Diseases, 2008
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986